Cargando…

Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial

OBJECTIVE: To evaluate the efficacy of aluminum-formulated intralymphatic glutamic acid decarboxylase (GAD-alum) therapy combined with vitamin D supplementation in preserving endogenous insulin secretion in all patients with type 1 diabetes (T1D) or in a genetically prespecified subgroup. RESEARCH D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ludvigsson, Johnny, Sumnik, Zdenek, Pelikanova, Terezie, Nattero Chavez, Lia, Lundberg, Elena, Rica, Itxaso, Martínez-Brocca, Maria A., Ruiz de Adana, Marisol, Wahlberg, Jeanette, Katsarou, Anastasia, Hanas, Ragnar, Hernandez, Cristina, Clemente León, Maria, Gómez-Gila, Ana, Lind, Marcus, Lozano, Marta Ferrer, Sas, Theo, Samuelsson, Ulf, Pruhova, Stepanka, Dietrich, Fabricia, Puente Marin, Sara, Nordlund, Anders, Hannelius, Ulf, Casas, Rosaura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2021
Materias:	Emerging Therapies: Drugs and Regimens
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323180/ https://www.ncbi.nlm.nih.gov/pubmed/34021020 http://dx.doi.org/10.2337/dc21-0318

Ejemplares similares

Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2
por: Nowak, Christoph, et al.
Publicado: (2022)

Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype
por: Puente-Marin, Sara, et al.
Publicado: (2023)

Association between treatment effect on C‐peptide preservation and HbA1c in meta‐analysis of glutamic acid decarboxylase (GAD)‐alum immunotherapy in recent‐onset type 1 diabetes
por: Nowak, Christoph, et al.
Publicado: (2022)

Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes
por: Tavira, Beatriz, et al.
Publicado: (2018)

Combined vitamin D, ibuprofen and glutamic acid decarboxylase-alum treatment in recent onset Type I diabetes: lessons from the DIABGAD randomized pilot trial
por: Ludvigsson, Johnny, et al.
Publicado: (2020)

Intralymphatic immunotherapy
por: Senti, Gabriela, et al.
Publicado: (2015)

Intralymphatic Histiocytosis
por: Garcia-Mouronte, Emilio, et al.
Publicado: (2022)

Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes
por: Hannelius, Ulf, et al.
Publicado: (2020)

Intralymphatic GAD-alum Injection Modulates B Cell Response and Induces Follicular Helper T Cells and PD-1+ CD8+ T Cells in Patients With Recent-Onset Type 1 Diabetes
por: Barcenilla, Hugo, et al.
Publicado: (2022)

Two Cases of Diabetic Ketoacidosis in HNF1A-MODY Linked to Severe Dehydration: Is it time to change the diagnostic criteria for MODY?
por: Pruhova, Stepanka, et al.
Publicado: (2013)

Response to Letter to the Editor from Youn Hee Jee: “Familial Short Stature - A Novel Phenotype of Growth Plate Collagenopathies”
por: Plachy, Lukas, et al.
Publicado: (2021)

Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocol
por: Ludvigsson, Johnny, et al.
Publicado: (2022)

Intralymphatic Histiocytosis: An Unusual Presentation
por: Blackwell, Timothy J., et al.
Publicado: (2021)

The Transplantability of Tumours by Intravenous and Intralymphatic Routes
por: Wallace, A. C., et al.
Publicado: (1965)

Papillary intralymphatic angioendothelioma: Dabska tumor()()
por: Silva, Thadeu Santos, et al.
Publicado: (2020)

Neutrophil Extracellular Trap Induced Dendritic Cell Activation Leads to Th1 Polarization in Type 1 Diabetes
por: Parackova, Zuzana, et al.
Publicado: (2020)

Elevated Biomarkers of NETosis in the Serum of Pediatric Patients With Type 1 Diabetes and Their First-Degree Relatives
por: Klocperk, Adam, et al.
Publicado: (2021)

Search for a time- and cost-saving genetic testing strategy for maturity-onset diabetes of the young
por: Dusatkova, Petra, et al.
Publicado: (2022)

The disposition of cytotoxic agents after intralymphatic infusion.
por: Calnan, J. S., et al.
Publicado: (1967)

Papillary intralymphatic angioendothelioma: An extremely rare tumor
por: Kaplan, Güven Ozan, et al.
Publicado: (2021)

Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients
por: Casas, Rosaura, et al.
Publicado: (2020)

Data on microbial DNA-induced IL-1β production in monocytes of type 1 diabetes patients
por: Zentsova, Irena, et al.
Publicado: (2019)

Allergen-specific intralymphatic immunotherapy in human and animal studies
por: Kim, Seon Tae, et al.
Publicado: (2017)

Intralymphatic Histiocytosis Associated with Osteoarthritis: A Case Report
por: Koo, Taehan, et al.
Publicado: (2022)

Familial Short Stature - a Novel Phenotype of Growth Plate Collagenopathies
por: Plachy, Lukas, et al.
Publicado: (2021)

Stratifying the Genetic Aetiology in Children Born Small for Gestational Age With Persistent Short Stature (SGA-SS)
por: Toni, Ledjona, et al.
Publicado: (2021)

Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors
por: Castle, Jessica R., et al.
Publicado: (2018)

Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study
por: Klubo-Gwiezdzinska, Joanna, et al.
Publicado: (2018)

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies
por: Peters, Anne L., et al.
Publicado: (2020)

Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA(1c), in Patients With Type 2 Diabetes
por: Ali, Ali Muhammed, et al.
Publicado: (2020)

Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6–17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial
por: Danne, Thomas, et al.
Publicado: (2020)

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial
por: Rosenstock, Julio, et al.
Publicado: (2020)

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
por: Perkovic, Vlado, et al.
Publicado: (2020)

Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
por: Wexler, Deborah J., et al.
Publicado: (2019)

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes
por: van Raalte, Daniël H., et al.
Publicado: (2019)

Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial
por: Watada, Hirotaka, et al.
Publicado: (2020)

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
por: Garvey, W. Timothy, et al.
Publicado: (2020)

Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
por: Schwartz, Gregory G., et al.
Publicado: (2020)

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
por: Frias, Juan P., et al.
Publicado: (2021)

Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study
por: Blonde, Lawrence, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fr3aosj74tbem1o7iuk6p78cu9